pamidronate has been researched along with Disease Models, Animal in 39 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alendronate is an aminobisphosphonate that acts as a potent inhibitor of osteoclastic bone resorption." | 5.29 | Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. ( Azuma, Y; Kiyoki, M; Ohta, T; Okabe, K; Oue, Y; Sato, H; Tsuchimoto, M, 1995) |
| " Bone cancer was induced by intra-tibial injections of murine mammary carcinoma cells (4T1) in immunocompetent BALB/c mice and treated intraperitoneally for up to 5 weeks with vehicle, rapamycin or pamidronate (a bisphosphonate currently used to reduce bone loss in bone cancer patients)." | 3.80 | Osteolysis and pain due to experimental bone metastases are improved by treatment with rapamycin. ( Abdelaziz, DM; Komarova, SV; Stone, LS, 2014) |
| "Pamidronate treatment had positive effects on skeletal muscle in the Mdx mice with decreased serum and muscle creatine kinase and evidence of improved muscle histology and grip strength." | 2.82 | Positive effects of bisphosphonates on bone and muscle in a mouse model of Duchenne muscular dystrophy. ( Grynpas, MD; Mitchell, J; Sugamori, KS; Yoon, SH, 2016) |
| " At this point, closed fractures were made using an Einhorn apparatus, and bisphosphonate dosing was continued until the experimental endpoint." | 1.56 | Pretreatment with Pamidronate Decreases Bone Formation but Increases Callus Bone Volume in a Rat Closed Fracture Model. ( Little, DG; McDonald, MM; Mikulec, K; Morse, A; Munns, CF; Schindeler, A, 2020) |
| " Pre-treatment with the bisphosphonate pamidronate started at 4 weeks of age over a period of 2 weeks or 6 weeks (cumulative dose 8 mg/kg for both) to assess the effectiveness of the two dosing regimens in ameliorating glucocorticoid-induced bone loss." | 1.51 | Pre-treatment with Pamidronate Improves Bone Mechanical Properties in Mdx Mice Treated with Glucocorticoids. ( Chen, J; Grynpas, MD; Mitchell, J; Yoon, SH, 2019) |
| "Pamidronate treatment protected mice from cortical bone loss but did not increase bone strength." | 1.43 | Prophylactic pamidronate partially protects from glucocorticoid-induced bone loss in the mdx mouse model of Duchenne muscular dystrophy. ( Chen, J; Grynpas, MD; Mitchell, J; Yoon, SH, 2016) |
| " However, complications associated with long-term administration of bisphosphonates, such as nonunion after pelvic insufficiency fracture or osteonecrosis of the jaw, have been recently reported in the literature." | 1.34 | High concentrations of pamidronate in bone weaken the mechanical properties of intact femora in a rat model. ( Choo, KS; Kim, JS; Ryu, JH; Won, JH; Yang, KH; Yoon, HK, 2007) |
| "Pamidronate treatment reduced tumor burden as assessed at autopsy by imaging and biomarkers." | 1.33 | Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP. ( Barken, I; Burton, DW; Deftos, LJ; Geller, J; Hastings, RH; Hoffman, RM; Jiang, P; Yang, M, 2005) |
| "Hypercalcemia was induced either by sc inoculation of syngeneic colon (C-26) adenocarcinoma cells or by sc injection of high-dose recombinant PTHrP (0." | 1.33 | The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. ( Adamu, S; Asuncion, F; Capparelli, C; Dunstan, CR; Geng, Z; Grisanti, M; Kostenuik, PJ; Morony, S; Starnes, C; Tan, HL; Warmington, K; Weimann, B, 2005) |
| "Nephrocalcinosis was identified in 14 of 20 kidneys of rabbits infused with pamidronate, but was not detected in the 20 kidneys of those rabbits infused with zoledronic acid." | 1.31 | Bisphosphonates and nephrocalcinosis in a rabbit leg lengthening model: a histological and therapeutic comparison. ( Cooke-Yarborough, C; Little, DG; Smith, NC; Williams, PR, 2001) |
| " Older and newer-generation bisphosphonates have an inhibitory effect on calcium oxalate urolithiasis that is demonstrable at relatively infrequent dosing intervals in vivo." | 1.30 | Inhibition of calcium oxalate urolithiasis in a rat model of lithogenesis using bisphosphonates. ( Gupta, M; Smith, AD; Tuncay, OL; Valderrama, E, 1997) |
| "Alendronate is an aminobisphosphonate that acts as a potent inhibitor of osteoclastic bone resorption." | 1.29 | Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. ( Azuma, Y; Kiyoki, M; Ohta, T; Okabe, K; Oue, Y; Sato, H; Tsuchimoto, M, 1995) |
| "Immobilization in this model induces osteopenia and increases turnover in cancellous bone." | 1.29 | The effect of pamidronate in a new model of immobilization in the dog. ( Grynpas, MD; Kasra, M; Pritzker, KP; Renlund, R, 1995) |
| "Thus, the increased bone resorption, which is a consequence of estrogen-deficiency, entrains increased bone formation, which masks a simultaneous reduction in estrogen-dependent bone formation." | 1.28 | Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation. ( Chambers, TJ; Chow, J; Colston, KW; Tobias, JH, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.13) | 18.7374 |
| 1990's | 8 (20.51) | 18.2507 |
| 2000's | 12 (30.77) | 29.6817 |
| 2010's | 15 (38.46) | 24.3611 |
| 2020's | 2 (5.13) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Morse, A | 1 |
| McDonald, MM | 1 |
| Mikulec, K | 1 |
| Schindeler, A | 1 |
| Munns, CF | 1 |
| Little, DG | 3 |
| Spirlandeli, AL | 1 |
| Dick-de-Paula, I | 1 |
| Zamarioli, A | 1 |
| Jorgetti, V | 1 |
| Ramalho, LNZ | 1 |
| Nogueira-Barbosa, MH | 1 |
| Volpon, JB | 1 |
| Jordão, AA | 1 |
| Cunha, FQ | 1 |
| Fukada, SY | 1 |
| de Paula, FJA | 1 |
| Olvera, D | 2 |
| Stolzenfeld, R | 2 |
| Marini, JC | 1 |
| Caird, MS | 2 |
| Kozloff, KM | 2 |
| Chen, J | 2 |
| Yoon, SH | 3 |
| Grynpas, MD | 4 |
| Mitchell, J | 3 |
| Fisher, E | 1 |
| Nolan, B | 1 |
| Abdelaziz, DM | 1 |
| Stone, LS | 1 |
| Komarova, SV | 1 |
| Ma, ZY | 1 |
| Wang, YX | 1 |
| Dharnidharka, VR | 1 |
| Mohanakumar, T | 1 |
| Sugamori, KS | 1 |
| Menzdorf, L | 1 |
| Weuster, M | 1 |
| Klüter, T | 1 |
| Brüggemann, S | 1 |
| Behrendt, P | 1 |
| Fitchen-Oestern, S | 1 |
| Varoga, D | 1 |
| Seekamp, A | 1 |
| Purcz, N | 1 |
| Glueer, CC | 1 |
| Pufe, T | 1 |
| Lippross, S | 1 |
| Movila, A | 1 |
| Mawardi, H | 2 |
| Nishimura, K | 1 |
| Kiyama, T | 1 |
| Egashira, K | 1 |
| Kim, JY | 1 |
| Villa, A | 1 |
| Sasaki, H | 1 |
| Woo, SB | 2 |
| Kawai, T | 2 |
| Rao, SH | 1 |
| Evans, KD | 1 |
| Oberbauer, AM | 1 |
| Martin, RB | 1 |
| Dayer, R | 1 |
| Brennan, TC | 1 |
| Rizzoli, R | 1 |
| Ammann, P | 1 |
| Senel, FC | 1 |
| Kadioglu Duman, M | 1 |
| Muci, E | 1 |
| Cankaya, M | 1 |
| Pampu, AA | 1 |
| Ersoz, S | 1 |
| Gunhan, O | 1 |
| Urrutia, J | 1 |
| Briceno, J | 1 |
| Carmona, M | 1 |
| Olavarria, F | 1 |
| Hodgson, F | 1 |
| Giro, G | 1 |
| Kajiya, M | 1 |
| Ohta, K | 1 |
| Almazrooa, S | 1 |
| Alshwaimi, E | 1 |
| Nishimura, I | 1 |
| Herring, P | 1 |
| Ingels, J | 1 |
| Carbone, LD | 1 |
| Barrow, KD | 1 |
| Osborn, D | 1 |
| Dietzen, DJ | 1 |
| Pifer, L | 1 |
| Burton, DW | 1 |
| Geller, J | 1 |
| Yang, M | 1 |
| Jiang, P | 1 |
| Barken, I | 1 |
| Hastings, RH | 1 |
| Hoffman, RM | 1 |
| Deftos, LJ | 1 |
| Wada, N | 1 |
| Ishii, S | 1 |
| Ikeda, T | 1 |
| Kitajima, M | 1 |
| Morony, S | 1 |
| Warmington, K | 1 |
| Adamu, S | 1 |
| Asuncion, F | 1 |
| Geng, Z | 1 |
| Grisanti, M | 1 |
| Tan, HL | 1 |
| Capparelli, C | 1 |
| Starnes, C | 1 |
| Weimann, B | 1 |
| Dunstan, CR | 1 |
| Kostenuik, PJ | 1 |
| Kumar, D | 1 |
| Kumar, V | 1 |
| Howman-Giles, RB | 1 |
| Wong, E | 1 |
| Ali, SO | 1 |
| Yang, KH | 1 |
| Won, JH | 1 |
| Yoon, HK | 1 |
| Ryu, JH | 1 |
| Choo, KS | 1 |
| Kim, JS | 1 |
| Cheng, PT | 1 |
| Chan, C | 1 |
| Müller, K | 1 |
| Azuma, Y | 1 |
| Sato, H | 1 |
| Oue, Y | 1 |
| Okabe, K | 1 |
| Ohta, T | 1 |
| Tsuchimoto, M | 1 |
| Kiyoki, M | 1 |
| Kasra, M | 1 |
| Renlund, R | 1 |
| Pritzker, KP | 1 |
| Green, J | 1 |
| Gupta, M | 1 |
| Tuncay, OL | 1 |
| Valderrama, E | 1 |
| Smith, AD | 1 |
| Diel, IJ | 1 |
| Lin, CL | 1 |
| Moniz, C | 1 |
| Chow, JW | 1 |
| Moran, EL | 1 |
| Fornasier, TL | 1 |
| Bogoch, TR | 1 |
| Clohisy, DR | 1 |
| O' Keefe, PF | 1 |
| Ramnaraine, ML | 1 |
| Williams, PR | 1 |
| Smith, NC | 1 |
| Cooke-Yarborough, C | 1 |
| Rodriguez, N | 1 |
| Bailey, BN | 1 |
| Martin, MB | 1 |
| Oldfield, E | 1 |
| Urbina, JA | 1 |
| Docampo, R | 1 |
| Chow, J | 1 |
| Tobias, JH | 1 |
| Colston, KW | 1 |
| Chambers, TJ | 1 |
| Nishijima, Y | 1 |
| Nemoto, R | 1 |
| Koiso, K | 1 |
| Webb, CL | 2 |
| Schoen, FJ | 2 |
| Levy, RJ | 2 |
| Benedict, JJ | 1 |
| Linden, JA | 1 |
1 review available for pamidronate and Disease Models, Animal
| Article | Year |
|---|---|
[Bisphosphonates in the adjuvant therapy of breast cancer-- pathophysiology, animal models, and clinical experiences].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Bone and Bones; Bone Density; Bone Neoplasms; | 1998 |
2 trials available for pamidronate and Disease Models, Animal
| Article | Year |
|---|---|
Positive effects of bisphosphonates on bone and muscle in a mouse model of Duchenne muscular dystrophy.
Topics: Animals; Anti-Inflammatory Agents; Biomechanical Phenomena; Body Weight; Bone and Bones; Bone Densit | 2016 |
[Bisphosphonates in the adjuvant therapy of breast cancer-- pathophysiology, animal models, and clinical experiences].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Bone and Bones; Bone Density; Bone Neoplasms; | 1998 |
37 other studies available for pamidronate and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Pretreatment with Pamidronate Decreases Bone Formation but Increases Callus Bone Volume in a Rat Closed Fracture Model.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bony Callus; Disease Model | 2020 |
Hepatic Osteodystrophy: The Mechanism of Bone Loss in Hepatocellular Disease and the Effects of Pamidronate Treatment.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling | 2017 |
Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies; Biomechanical Phenomena; Cancellous Bone; | 2018 |
Pre-treatment with Pamidronate Improves Bone Mechanical Properties in Mdx Mice Treated with Glucocorticoids.
Topics: Animals; Biomechanical Phenomena; Bone and Bones; Bone Diseases, Metabolic; Cancellous Bone; Cortica | 2019 |
Pamidronate Administration During Pregnancy and Lactation Induces Temporal Preservation of Maternal Bone Mass in a Mouse Model of Osteogenesis Imperfecta.
Topics: Animals; Bone Density; Disease Models, Animal; Female; Humans; Lactation; Mice; Osteogenesis; Osteog | 2019 |
Osteolysis and pain due to experimental bone metastases are improved by treatment with rapamycin.
Topics: Animals; Antibiotics, Antineoplastic; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, T | 2014 |
[Establishment of bisphosphonate-related osteonecrosis of the jaw model in rats and preliminary analysis of its etiological mechanism].
Topics: Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cell | 2014 |
New approaches to treating B-cell cancers induced by Epstein-Barr virus.
Topics: Animals; Antineoplastic Agents; B-Lymphocytes; Diphosphonates; Disease Models, Animal; Epstein-Barr | 2015 |
Local pamidronate influences fracture healing in a rodent femur fracture model: an experimental study.
Topics: Animals; Bone Density Conservation Agents; Collagen; Diphosphonates; Disease Models, Animal; Female; | 2016 |
Prophylactic pamidronate partially protects from glucocorticoid-induced bone loss in the mdx mouse model of Duchenne muscular dystrophy.
Topics: Animals; Biomechanical Phenomena; Body Weight; Bone Remodeling; Bone Resorption; Calcification, Phys | 2016 |
Possible pathogenic engagement of soluble Semaphorin 4D produced by γδT cells in medication-related osteonecrosis of the jaw (MRONJ).
Topics: Animals; Antibodies, Monoclonal; Antigens, CD; Bisphosphonate-Associated Osteonecrosis of the Jaw; D | 2016 |
Bisphosphonate treatment in the oim mouse model alters bone modeling during growth.
Topics: Animals; Bone Development; Bone Remodeling; Diphosphonates; Disease Models, Animal; Dose-Response Re | 2008 |
PTH improves titanium implant fixation more than pamidronate or renutrition in osteopenic rats chronically fed a low protein diet.
Topics: Animal Nutritional Physiological Phenomena; Animals; Body Weight; Bone Density Conservation Agents; | 2010 |
Jaw bone changes in rats after treatment with zoledronate and pamidronate.
Topics: Animals; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Femur; Im | 2010 |
Effect of a single dose of pamidronate administered at the time of surgery in a rabbit posterolateral spinal fusion model.
Topics: Animals; Bone Density Conservation Agents; Bone Regeneration; Bone Remodeling; Bone Transplantation; | 2010 |
A role of oral bacteria in bisphosphonate-induced osteonecrosis of the jaw.
Topics: Animals; Anti-Bacterial Agents; Apoptosis; Bone Density Conservation Agents; Cell Movement; Cell Sur | 2011 |
Lack of efficacy of the combination of pamidronate and vitamin D on regression of prostate cancer in the Dunning rat model.
Topics: Animals; Anti-Inflammatory Agents; Diphosphonates; Disease Models, Animal; Drug Therapy, Combination | 2003 |
Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Calcium; Carrier | 2005 |
Inhibition of bone metastasis from breast cancer with pamidronate resulting in reduction of urinary pyridinoline and deoxypyridinoline in a rat model.
Topics: Amino Acids; Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Cell Line, T | 2004 |
The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Resorption; Calcium; Carrier Proteins; Cell Lin | 2005 |
Evaluation of biodistribution by local versus systemic administration of 99mTc-labeled pamidronate.
Topics: Administration, Topical; Animals; Bone Density Conservation Agents; Diphosphonates; Disease Models, | 2006 |
High concentrations of pamidronate in bone weaken the mechanical properties of intact femora in a rat model.
Topics: Animals; Bone Density Conservation Agents; Diphosphonates; Disease Models, Animal; Female; Femur; Fr | 2007 |
Cyclical treatment of osteopenic ovariectomized adult rats with PTH(1-34) and pamidronate.
Topics: Analysis of Variance; Animals; Bone and Bones; Bone Development; Bone Diseases, Metabolic; Diphospho | 1995 |
Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.
Topics: Alendronate; Animals; Autoradiography; Bone and Bones; Bone Resorption; Calcium; Carbon Radioisotope | 1995 |
The effect of pamidronate in a new model of immobilization in the dog.
Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Diseases, Metabolic; Diphosphonates; Disease Mo | 1995 |
Zoledronate: the preclinical pharmacology.
Topics: Animals; Bone Resorption; Cholecalciferol; Depression, Chemical; Diphosphonates; Disease Models, Ani | 1996 |
Inhibition of calcium oxalate urolithiasis in a rat model of lithogenesis using bisphosphonates.
Topics: Analgesics, Non-Narcotic; Animals; Calcium; Calcium Oxalate; Clodronic Acid; Creatinine; Diphosphona | 1997 |
Treatment with fluoride or bisphosphonates prevents bone loss associated with colitis in the rat.
Topics: Animals; Anti-Inflammatory Agents; Colitis; Diphosphonates; Disease Models, Animal; Inflammatory Bow | 2000 |
Pamidronate prevents bone loss associated with carrageenan arthritis by reducing resorptive activity but not recruitment of osteoclasts.
Topics: Animals; Anti-Inflammatory Agents; Arthritis; Bone and Bones; Bone Resorption; Carrageenan; Diphosph | 2000 |
Pamidronate decreases tumor-induced osteoclastogenesis in osteopetrotic mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Bone Resorption; Cell Count; Diphosphonat | 2001 |
Bisphosphonates and nephrocalcinosis in a rabbit leg lengthening model: a histological and therapeutic comparison.
Topics: Animals; Bone Density; Bone Regeneration; Diphosphonates; Disease Models, Animal; Imidazoles; Kidney | 2001 |
Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate.
Topics: Animals; Antiprotozoal Agents; Diphosphonates; Disease Models, Animal; DNA, Kinetoplast; Injections, | 2002 |
Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation.
Topics: Animals; Bone Resorption; Diphosphonates; Disease Models, Animal; Estradiol; Female; Osteogenesis; O | 1992 |
[Establishment of a model to evaluate inhibition of bone resorption induced by bladder tumor (MBT-2) in mice].
Topics: Animals; Bone Neoplasms; Bone Resorption; Diphosphonates; Disease Models, Animal; Female; Mice; Neop | 1990 |
Covalent binding of aminopropanehydroxydiphosphonate to glutaraldehyde residues in pericardial bioprosthetic tissue: stability and calcification inhibition studies.
Topics: Aldehydes; Animals; Bioprosthesis; Calcinosis; Diphosphonates; Disease Models, Animal; Glutaral; Hea | 1989 |
Inhibition of bioprosthetic heart valve calcification with aminodiphosphonate covalently bound to residual aldehyde groups.
Topics: Aldehydes; Animals; Aortic Valve Stenosis; Bioprosthesis; Calcinosis; Cattle; Diphosphonates; Diseas | 1988 |